Merriman Curhan Ford Initiates Coverage on Antares Pharma (AIS) with a Buy; Cutting Edge Drug Delivery Business
More News related to AIS
- Skymark Research Initiates Independent Research Coverage on Antares Pharma, Inc.
- ANTARES PHARMA Partner, Teva USA, Introduces New Resources to Support Use of ANTARES' Patient-Friendly Injector for Growth Hormone Deficiency in Children
- Antares Pharma Expands Executive Team and Appoints Pavan Handa as Senior Vice President of Business Development
- Antares Pharma (AIS) Announces Successful Phase 2 for NES/E2 Utilizing ATD Gel System
- Antares Pharma and Population Council Announce Positive Phase 2 Trial Results
More News related to TEVA
- BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
- Teva Pharma (TEVA) Extends Oral Laquinimod Marketing and Distribution Rights to Nordic and Baltic Regions
- Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions
- Teva Pharma (TEVA) Settles with Ven-A-Care; To Record Charge of $315M for Q409
- Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
Merriman Curhan Ford initiates coverage on Antares Pharma, Inc. (NYSE: AIS) with a Buy.
Merriman analyst says, "We believe Antares represents a strong value play in the drug delivery space. The company currently has two approved and commercialized delivery technologies. Antares currently has strong partnerships with several companies including Ferring Pharmaceuticals and Teva Pharmaceuticals (Nasdaq: TEVA), with which the company has multiple ongoing drug collaborations. We believe the company’s superior delivery technology and aggressive management team will be able to drive Antares to profitability in the near term. The company currently has over 10 programs in differing stages of development."
To see more analyst ratings on AIS Click Here.
Antares Pharma, Inc. operates as a specialty drug delivery/pharmaceutical company.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
